Testosterone improves urinary tract symptoms and sexual function in patients with nonfunctional pituitary macroadenomas

  • Vargas-Ortega G & al.
  • Int J Endocrinol
  • 01/01/2019

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Testosterone therapy is associated with improved lower urinary track symptoms and sexual function in patients with nonfunctional pituitary macroadenomas and hypogonadotropic hypogonadism.

Why this matters

  • Hypogonadotropic hypogonadism is common in patients with nonfunctional pituitary macroadenomas, but the specific effects of testosterone therapy have not been well studied in this population.

Key results

  • Testosterone therapy was associated with increased triglyceride levels (P=.03), dyslipidemia (P=.03), and metabolic syndrome (P=.05), as well as hematocrit (P=.001), hemoglobin (P=.001), and prostatic-specific antigen (P=.02) compared with baseline.
  • Testosterone therapy was associated with improved penetration quality (P=.05), erection after penetration (P=.02), completion of intercourse (P=.03), and satisfaction after intercourse (P=.01) compared with baseline.
  • Testosterone therapy was associated with reduced urinary intermittency (P=.02), urgency (P=.01), and episodes of nocturia (P=.02) compared with baseline.

Study design

  • 101 male patients with nonfunctional pituitary macroadenomas and hypogonadotropic hypogonadism treated with testosterone therapy were included.
  • Funding: None disclosed.

Limitations

  • Retrospective study.
  • No control population.